Press Archive - Arriello

Pharmacovigilance under scrutiny.

Despite pharmacovigilance legislation being in place for nearly a decade, many companies are still struggling to fulfill obligations. Arriello's Vanessa Fachada Oliveira writes for Pharmaceutical Technology

Streamlining Pharmacovigilance.

Streamlining Pharmacovigilance: Why the Inertia? via Pharmaceutical Executive and Arriello's Director of Drug Safety Peter Kohut analyse the findings of a survey on how life sciences companies are capitalizing on opportunities to transform workload and data quality management using the latest smart technology.

Why aren’t more companies automating PV data capture?

Why are Safety & Pharmacovigilance departments lagging in their application of smart technology, when the pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are vast, asks John Price, a life sciences regulatory and safety consultant and advisor to Arriello.

Raising the bar in pharmacovigilance and regulatory outsourcing.

It’s all too easy to underestimate the importance of tight project management when the work being outsourced is something other than clinical trials. Yet, whether the processes involved concern international pharmacovigilance or regulatory information filing, Anna Lukyanova, COO of Arriello, warns life sciences firms not to leave outcomes to chance.

Pharmacovigilance under scrutiny.

Automating PV data capture, press article by John Price

Pharma Technology Focus John Price writes for Arriello on why more companies should be automating PV data capture. Read more here!

Pharmacovigilance 2.0: Reskilling for the digital age.

Education, training and recruitment strategies need to adapt quickly if the life sciences industry is going to have fit-for-purpose PV teams in future – made up of people who know how to exploit technology to deliver optimum results. Arriello's COO Anna Lukyanova assesses the new skillsets and suggests how the industry might address it.

The Global–Local Continuum: Tips for a joined-up approach to regulatory & PV outsourcing.

Local affiliates are arguably just as in need of outsourcing support as primary pharma locations. But drawing on such services should be frictionless, and involve close coordination with the vision and goals of HQ. Anna Lukyanova COO of Arriello, explores where biotech and pharma firms can go awry in their international service use, and offers tips on how to ease the transition for all.